Insights

Why the Race Oncology (ASX:RAC) share price surged 7% today

Race Oncology shares shot out of the starting blocks today after positive study results.
The post Why the Race Oncology (ASX:RAC) share price surged 7% today appeared first on The Motley Fool Australia. –

The Race Oncology Ltd (ASX: RAC) share price jumped out of the starting blocks today, shooting up 7% to a high of $3.66. This was after the biopharma company announced a key update on results from one of its research programs.

The Race Oncology share price has since lost some ground, however, and is currently trading at $3.46, still 2.37% higher than yesterday’s closing price.

Here’s what we know.

Positive melanoma study results

Race Oncology advised today that its anti-cancer drug label, Zantrene, was shown to be effective in destroying highly active skin cancer cells in mice.  

This followed promising results from its “collaborative preclinical melanoma research program” with the University of Newcastle.

The company said the program involved researchers exploring Zantrene’s effectiveness as a novel treatment for the malignant type of skin cancer known as melanoma.

Interim results demonstrated Zantrene to be “highly effective at killing a diverse range of high FTO producing melanoma cell subtypes”.

This means is that Zantrene is showing early signs of potentially becoming a treatment for melanoma.

However, there is still a whole wave of evidence to produce, and a mountain of regulatory headwinds to overcome before that becomes reality.

Nonetheless, key takeouts from the study include that Zantrene is “highly effective in killing melanoma cells at sub-chemotherapeutic levels”, and that it achieved these results at low concentrations.

Race Oncology believes the results were “highly supportive” of future clinical trials to investigate Zantrene’s use as a combination therapy in melanoma treatment.

Management commentary

Speaking on the announcement, Race Oncology CEO Phillip Lynch said the company was encouraged by its work so far:

While challenged by COVID-19 related shutdowns, we appreciate the encouraging and continued work from the team at the University of Newcastle.

Zantrene continues to positively surprise us – we are very pleased with these early results. Melanoma remains a difficult cancer to treat, and one that’s of particular relevance to the Australian community, so as we continue with this work, we look forward to learning more about our potential to offer new treatment options to patients.

Race Oncology share price snapshot

The Race Oncology share price has climbed 97% year to date and rallied 12.7% in the past month.

Over the past 12 months, Race Oncology shareholders have enjoyed a return of 339.4%, well ahead of the S&P/ASX 200 index (ASX: XJO)’s gain of about 25% in this time.

The post Why the Race Oncology (ASX:RAC) share price surged 7% today appeared first on The Motley Fool Australia.

Should you invest $1,000 in Race Oncology right now?

Before you consider Race Oncology, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Race Oncology wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Why is the Race Oncology (ASX:RAC) share price up 18% in a month?

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!